Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
Influenza Viruses
Introduction
Viruses are extremely minute sub-living organism, obligate intracellular parasites, seen on...
Pathogenic classification of Influenza Virus type A
Influenza Virus type A are classified according to their pathogenicity...
-2, 6 galactosialic acid present on the mucous membranes of respiratory system of human and
mammals "including swine“. It ...
Molecular Pathogenicity of Influenza viruses
Hemagglutinin facilitates the viral entry to inside the host cell through the...
The circulating epitopes and the predominant hosts
NeuraminidaseHemagglutinin
Predominant hostsSubtypePredominant hostsSub...
B-In Human
Acute infectious and contagious respiratory disease caused by H1N1 and characterized by
fever in 80% and chills...
4-The disease is transmitted by direct and direct contact. The mode of infection is by inhalation
of infected droplets. Mo...
Maintenance: Bird to bird - Persistence in environment.
Clinical Signs
• Incubation period 3-5 days.
• Severe depression w...
3-Hong Kong flu 1968 – H3N2 – 700000 died – 34000 died in USA.
4-Swin flu 1976 –- H1N1 --- few deaths.
5-The 1st record of...
‫آ‬‫ا‬ ‫ا‬ ‫اض‬ ‫أﻡ‬ ‫ﻡ‬ ‫ﻡ‬ ‫ا‬
‫أو‬-‫ا‬‫ر‬ ‫ــ‬
١-‫ي‬ ‫ا‬ ‫ن‬ ‫اﺉ‬ ‫ﺝ‬ ‫ا‬ ‫ا‬ ‫ﺕ‬ ‫ﺕ‬.
٢-‫ر‬ ‫أ‬ ‫ث‬ ‫ي‬ ‫ا‬ ‫ﺏ‬ ‫زة‬ ‫...
-‫أ‬ ‫أ‬ ‫ي‬ ‫ﺏ‬Binary ethylene Amine:‫دة‬‫ذ‬‫ات‬‫وب‬ ‫ﺉ‬ ‫ﺕ‬ ‫و‬ ‫ءة‬ ‫وآ‬ ‫دة‬ ‫ﺝ‬
‫ف‬ ‫ا‬Fragmentation‫ﺝ‬ ‫ا‬ ‫ا‬ ‫ع‬ ‫...
١-‫م‬ ‫ا‬ ‫دا‬ ‫ا‬ ‫ت‬ ‫ﺉ‬ ‫ا‬ ‫آ‬Homothermous‫ا‬ ‫ارة‬ ‫ا‬ ‫درﺝ‬ ‫ول‬ ‫ا‬ ‫ا‬ ‫ارة‬ ‫درﺝ‬ ‫ن‬surface
temperature‫ا‬ ‫ا‬ ‫...
‫ﻡ‬ ‫ا‬ ‫ت‬ ‫وا‬ ‫ا‬ ‫ت‬ ‫ا‬ ‫ﺏ‬ ‫ر‬ ‫ﻡ‬
‫ر‬ ‫ا‬ ‫أو‬‫ا‬ ‫ح‬ ‫ا‬‫ﻡ‬ ‫ا‬ ‫ح‬ ‫ا‬
‫ا‬ ‫آ‬ ‫ا‬LowHigh
‫ا‬‫ﺏ‬"٢-٣‫م‬"‫ﺏ‬"‫ا‬ ‫...
‫ا‬ ‫ا‬ ‫رة‬ ‫ا‬ ‫و‬‫ﺕ‬‫ا‬ ‫ه‬ ‫ا‬-‫ا‬ ‫ﺕ‬T-cytotoxic‫ا‬ ‫ﺝ‬ ‫ﺕ‬ ‫وا‬
‫ا‬ ‫ى‬ ‫وا‬-‫ة‬ ‫اآ‬ ‫ا‬ ‫ﺕ‬Memory T-cells‫ا‬ ‫و‬ ‫...
‫ا‬ ‫ا‬Passive Immunization
‫ة‬ ‫ه‬ ‫ا‬ ‫دة‬ ‫ا‬ ‫م‬ ‫ﺝ‬ ‫ا‬ ‫ض‬ ‫ﺏ‬ ‫ﺏ‬ ‫ا‬ ‫ر‬ ‫ا‬ ‫ء‬ ‫أ‬ ‫أي‬‫ن‬ ‫ا‬ ‫ا‬ ‫ه‬ ‫ل‬ ‫ا‬ ‫...
‫ا‬ ‫ا‬ ‫ح‬ ‫ع‬ ‫ا‬ ‫ص‬ ‫ﺵ‬ ‫ا‬
‫آ‬‫اض‬ ‫أ‬ ‫ت‬ ‫وآ‬ ‫ﺏ‬ ‫ا‬ ‫ا‬ ‫ﺕ‬ ‫ة‬ ‫ﺵ‬ ‫ﺝ‬ ‫ر‬ ‫ﺙ‬ ‫ض‬ ‫ﺕ‬ ‫وآ‬ ‫ا‬ ‫ط‬
‫ر‬ ‫ﺏ‬ ‫ن‬ ...
-‫ﺕ‬ ‫ة‬ ‫ل‬ ‫ﺏ‬ ‫ﺏ‬ ‫ا‬ ‫ص‬ ‫ﺵ‬ ‫ا‬ ‫ء‬ ‫ﺏ‬٢٤‫ر‬ ‫وا‬ ‫ب‬ ‫ه‬ ‫ا‬ ‫م‬ ‫و‬ ‫ا‬ ‫زوال‬ ‫ﺏ‬.
-‫ا‬ ‫وا‬ ‫ق‬ ‫ا‬ ‫وﺕ‬ ‫د‬ ‫ا‬ ...
Influenza viruses Dr Fares El khayat
Influenza viruses Dr Fares El khayat
Upcoming SlideShare
Loading in …5
×

Influenza viruses Dr Fares El khayat

Influenza viruses Dr Fares El khayat

  • Be the first to comment

Influenza viruses Dr Fares El khayat

  1. 1. Influenza Viruses Introduction Viruses are extremely minute sub-living organism, obligate intracellular parasites, seen only by electron microscope and classified into DNA and RNA viruses. 1-All DNA viruses are double-stranded except for Parvovirus. 2-All RNA viruses are single-stranded except for Birnavirus and Reovirus. 3-RNA viruses have no proof reading capacities so, they are unstable and the mutation rate is extremely high in them. 4-DNA viruses have well developed proof reading capacities so, they are stable, and the mutation rate is extremely low in them. 3-Replication of DNA viruses is nuclear while that of RNA viruses is cytoplasmic. Influenza Viruses and their diseases Influenza Viruses belong to Orthomyxoviridae "a part of order Myxoviruses" that infect the body only through the mucous membrane lining the duct systems as digestive, respiratory, urogenital as well as the eyes. Orthomyxoviridae are the true Myxoviruses that are characterized by: -Polymorphic "rounded or ovoid" with 80-120 nanometer diameter. -Single stranded segmented RNA = sss RNA. -Enveloped, sensitive to organic solvents, disinfectants and thermolabile hence they loss their pathogenicity in 3 hrs at 56 degree, in half an hour at 60 degree and in one second at 70 degree. Influenza viruses are classified according to the number of RNA segments and internal viral protein "Matrix = M + Non-structural protein = NSP" into three categories A, B, and C.
  2. 2. Pathogenic classification of Influenza Virus type A Influenza Virus type A are classified according to their pathogenicity into: 1- Highly pathogenic Influenza virus = HPAI: kill 8 from 16; 4-8 wks-old chicks intravenously injected with virus extract 1/10 through 10 days observation. They include H5 and H7 although some isolates contain H10 "H10N4 & H10N5". Clincopathologically, they spread rapidly among the susceptible hosts and cause extremely destructive diseases in the respiratory and digestive systems with high mortalities in short time. 2-Medium pathogenic Influenza virus = MPAI: kill 1-5 chicks from 16; 4-8 wks-old intravenously injected with virus extract 1/10 through 10 days observation. Some strains of them are used for manufacturing vaccines. 3-Low pathogenic Influenza virus = LPAI: they do not cause diseases or may cause very mild symptoms but if there is concurrent infection between any one of them with Mycoplasma spp. "Turkey & chickens" or Hemophilus spp." chickens", their pathogenicity will be exaggerated and may causes disease with mortalities. They do not contain H5 and H7. Viral receptors of Influenza Virus type A 1-Viruses are obligate intracellular parasites i.e. they can not cause a disease unless enter the host cell. 2-Viruses enter the host cells through specific windows “receptors”. 3-Each species of virus has its own specific viral receptors. 4-Influenza virus type A has three viral receptors: -2, 3 galactosialic acid present on the mucous membranes of respiratory and digestive system of poultry and swine. It is specific to avian types of Influenza virus.
  3. 3. -2, 6 galactosialic acid present on the mucous membranes of respiratory system of human and mammals "including swine“. It is specific to human types of Influenza virus. -1, 6 galactosialic acid present on the mucous membranes of respiratory system of swine. It is specific to swine types of Influenza virus. Viral Mixing Vessels Viral mixing vessels are the animals or birds that may be infected by more than one Influenza virus type A at the same time. There are three important mixing vessels for Influenza virus A. They constitute very dangerous threat to human and animal beings due to the probable genetic changes and production of new Influenza virus type A having the ability to induce an extremely destructive epidemic and pandemics. 1-Swine: they carry all types of Influenza virus A receptors i.e. 2, 3 galactosialic acid "avian type" + 2, 6 galactosialic acid "human type" + 1, 6 galactosialic acid "swine type". This means that they are able to suffer from co-infections either double or triple at the same time. Double infection as "avian + human types" or "avian + swine types" or "human + swine types". Triple infection as "avian + human + swine types". During the viruses multiplication inside the swine host body, genetic exchange and mixing may occur producing a new Influenza virus A having the ability for human to human transmission. This new Influenza virus type A is a pandemic virus. 2-Quail: some literatures mentioned that they contain avian types and human type receptors and may act as a mixing vessel for these two types producing a new pandemic Influenza virus type A having the ability for human to human transmission. 3-Human beings: some literatures mentioned that they contain may act as a mixing vessel for human and swine types producing a new pandemic Influenza virus type A having the ability for human to human transmission. NB: turkey and swine have a special unexplained relationship of exchange of influenza virus “avian types and swine types”. This relationship may act as a mixing vessel for these two types producing a new pandemic Influenza virus type A having the ability for human to human transmission.
  4. 4. Molecular Pathogenicity of Influenza viruses Hemagglutinin facilitates the viral entry to inside the host cell through the connection between the virus and sialic acid receptor. After connection, the virus is engulfed into the cell through a process known as endocytosis, after which, the invading virus is attached to the endosomes of the host cell and start the process of replication and multiplication with induction of the disease. The virus to be able to invade the host cell, hemagglutinin must be cleaved to H0 & H1. Process of cleavability is carried out by one of 2 mechanisms: -The natural mechanisms: in which, hemagglutinin is cleaved by: 1-Proteases: secreted only from lining cells of throat, trachea and lungs. 2-Plasmine: secreted from most cells of the body and sometimes induces the cleavability to HPIV containing H5 and H7. -Artificial mechanisms: in which, hemagglutinin is cleaved by trypsine secreted from Mycoplasma, Hemophilus and/or streptococcus if a concurrent infection occurs including one of these bacteria and low pathogenic Influenza virus A. Chacteristics of Influenza Virus type A I-Genetic reassortment: genetic changes occurring inside the mixing vessels producing a new pandemic influenza virus type A having the ability for human to human transmission. II-Virus mutation: Influenza virus type A is highly mutating virus in a relatively short period of time. Mutation of Influenza virus A has two kinds: -Antigenic drift = Minor changes: Slow mutation in one or two amino acids of the virus structure. It occurs either in H or N or never in both. -Antigenic shift = Major changes: Rapid mutation in the polypeptide chain of virus structure. It may occur in both H and N epitopes. It takes place in one of 10000 viruses and responsible for the recurrence of seasonal influenza. Ecosystem and Reservoirs of Influenza viruses The ecosystem of influenza viruses means their ability to circulate and transmit among different species of animal and birds and their ability for species jumping. This ecosystem includes: 1-Ducks as reservoirs for influenza viruses. 2-Marine mammals as whale and dolphin and land mammals as human, swine and equine as susceptible mammalian hosts to influenza viruses. 3-Avian species as turkeys, chickens and quails as susceptible hosts. 4-Migratory birds are trans-boundary agents to influenza viruses.
  5. 5. The circulating epitopes and the predominant hosts NeuraminidaseHemagglutinin Predominant hostsSubtypePredominant hostsSubtype -HumanPigBirdsN1-HumanPigBirdsH1 -HumanPigBirdsN2-HumanPigBirdsH2 ---BirdsN3HorseHumanPigBirdsH3 ---BirdsN4---BirdsH4 ---BirdsN5-Human-BirdsH5 ---BirdsN6---BirdsH6 Horse--BirdsN7HorseHuman-BirdsH7 Horse--BirdsN8---BirdsH8 ---BirdsN9-Human-BirdsH9 --------BirdsH10 --------BirdsH11 --------BirdsH12 --------BirdsH13 --------BirdsH14 --------BirdsH15 --------BirdsH16 Diseases of Influenza viruses 1-Avian influenza. 2- Swine Influenza. 3-Equine influenza. 4-Seasonal Influenza. Swine Influenza A-In swine: Acute infectious contagious respiratory disease of swine caused by H1N1, H1N2, H2N1 or H2N2. It causes high morbidity and low mortality "1-4%". H1N1 is isolated in 1930 in USA and about 25% of swine population is infected with it. H3N2 is isolated in 1998 and transmitted from human to swine. Swine are mixing vessels i.e. other avian and human type can circulate among swine and may produce a new pandemic influenza virus. The disease is transmitted by direct and direct contact. The mode of infection is by inhalation of infected droplets. The disease occurs all over the year but its incidence increases in fall and winter "from October till February".
  6. 6. B-In Human Acute infectious and contagious respiratory disease caused by H1N1 and characterized by fever in 80% and chills in 60% of cases, dry cough, chest pain, headache, vomiting, diarrhea and aches. The disease is more prevalent in fall and winter "from October till February". It was discovered in 1988 in a pregnant woman died due to pneumonia 8 days after the admission to the hospital. The study of the case concluded that this woman visited a pig exhibition 4 days before illness, and 3 nurses contacted with the dead woman were positive to swine influenza and 75% from exhibitors were also positive. The disease is transmitted by direct and direct contact with infected swine. The disease is transmitted from human to human. The mode of infection is by inhalation of infected droplets. The disease affects all ages but the seriousness is directed toward pregnant women, persons with chronic diseases and obese persons. Avian Influenza H5N1 virus Electron micrograph of avian influenza H5N1 virus Avian Influenza A-In Birds 1-The disease is discovered in Italy in 1887 and caused high mortality in birds "fowl plague". 2-The causative agent is denoted as a virus in 1902 but it is truly classified as influenza virus in 1955. The disease was present in Egypt in the fourteens and fifteenth and disappears in the sixteenth but it reemerges again in 2006. 3-The disease affects chickens, turkeys, quails, ostriches and zoo birds. It also affects swine, wheals, cats and rats. The migratory birds and aquatic birds are asymptomatic carriers. Pigeon are insusceptible.
  7. 7. 4-The disease is transmitted by direct and direct contact. The mode of infection is by inhalation of infected droplets. Mosquitoes and ticks transmit it mechanically. Swine transmit it biologically especially to turkeys. The incubation periods is 4-14 days. Natural Reservoirs of Influenza A Viruses How are these viruses transmitted and maintained in these species? Transmission: Fecal/Oral route Heavy fecal shedding by infected ducks - Long term persistence in water - Isolation of AIVs from surface water
  8. 8. Maintenance: Bird to bird - Persistence in environment. Clinical Signs • Incubation period 3-5 days. • Severe depression with decreased food and water consumption. • Drastic decline in egg production. • Many birds affected. • Dehydration. • Huddling. • Subcutaneous swelling of the head and neck area. • Nasal and oral cavity discharge. • Ruffled feathers. • Swollen, cyanotic (blue) combs and wattles. Conjunctivitis with respiratory sign. II-Highly pathogenic avian influenza The disease spread rapidly, morbidity rate reach 100% with mortality may reach 100% within 4-5 days. The mortality is characterized by its exponential fashion. General signs as enlargement of head with facial edema, cyanosis of unfeathered parts and drop in egg production. Respiratory signs as coughing, sneezing and nasocular discharge. Digestive signs as greenish diarrhea. Nervous signs as ataxia. Clinical Symptoms of Avian influenza B-In human History of influenza in human 1-Spanish flu 1918 – H1N1 – 40 million died – 1 million died in USA. 2-Asian flu 1958 – H2N2 – 1 million died – 70000 died in USA.
  9. 9. 3-Hong Kong flu 1968 – H3N2 – 700000 died – 34000 died in USA. 4-Swin flu 1976 –- H1N1 --- few deaths. 5-The 1st record of direct infection from birds 1997 – H5N1 -- 6 died -- Hong Kong. 6-Avian influenza in Egypt 2005. Conditions of direct infection from birds: Immunosuppression, Co-infections with trypsine producers, the permanent existence and contact with birds and chronic diseases. Incubation period: 1-3 days. Symptoms in human: fever "40 C" with chills continue 1-2 weeks. Dry cough, chest pain, headache, tympani, constipation and aches. Seasonal flu ‫ا‬ ‫ا‬ ‫ا‬ ‫ﻡ‬ ‫ة‬ ‫اع‬ ‫ا‬ ‫ا‬ ‫ا‬ ‫ت‬ ‫و‬ ‫أ‬ ‫دة‬ ‫و‬ ‫وى‬ ‫ا‬ ‫ا‬ ‫ا‬A‫أ‬‫و‬B‫أ‬‫و‬C‫ع‬ ‫ا‬ ‫و‬A‫أن‬H1N1‫و‬ H3N2‫ات‬ ‫ا‬ ‫أآ‬ ‫ه‬‫ا‬ ‫ا‬ ‫ا‬ ‫ت‬ ‫أ‬ ‫ا‬ ‫ﺏ‬C‫و‬ ‫ا‬ ‫ا‬ ‫وﺙ‬ ‫أ‬‫ت‬ ‫ن‬ ‫ا‬ ‫ت‬ ‫و‬ ‫ا‬ ‫إ‬ ‫ﺕ‬ ‫ا‬ ‫ا‬ ‫ا‬A‫و‬.B ‫ﺕ‬‫ء‬ ‫وا‬ ‫ا‬ ‫ء‬ ‫أﺙ‬ ‫ث‬‫ﺏ‬‫و‬ ‫اض‬ ‫ﺏ‬ ‫ﺏ‬ ‫وا‬ ‫وا‬ ‫ل‬ ‫ا‬ ‫ر‬ ‫ﺹ‬ ‫ﺏ‬ ‫ة‬ ‫و‬ ‫وﺕ‬ ‫ا‬‫اوح‬ ‫ﺏ‬ ‫ق‬ ‫ا‬ ‫ل‬٢٥٠٠٠٠‫إ‬٥٠٠٠٠٠‫ت‬ ‫ا‬ ‫وﺕ‬ ‫ة‬ ‫و‬‫ا‬ ‫ﺏ‬ ‫ا‬ ‫ان‬ ‫ا‬ ‫ا‬ ‫ﺏ‬ ‫ﺕ‬ ‫ا‬ ‫ا‬٦٥‫دورا‬ ‫و‬ ‫ا‬ ‫ا‬ ‫ا‬ ‫ت‬ ‫و‬ ‫ور‬ ‫ﺕ‬ ‫ار‬ ‫ا‬ ‫ا‬ ‫ان‬ ‫ﺏ‬ ‫ﺏ‬ ‫و‬ ‫ق‬‫أو‬ ‫ة‬ ‫روة‬ ‫ا‬ ‫ر‬ ‫ا‬ ‫ا‬ ‫ل‬ ‫ﺕ‬. ‫ﺏ‬ ‫ا‬ ‫ت‬ ‫ا‬:‫ا‬ ‫ا‬ ‫ت‬ ‫ا‬ ‫آ‬‫وا‬ ‫أ‬ ‫ل‬‫ر‬‫ق‬٦٥‫أآ‬ ‫ه‬ ‫اض‬ ‫ﺏ‬ ‫ﺏ‬ ‫وا‬ ‫وى‬ ‫ا‬ ‫ت‬ ‫ﺏ‬ ‫ﺏ‬ ‫ﺹ‬ ‫ا‬ ‫ت‬ ‫ا‬. ‫وى‬ ‫ا‬ ‫ر‬ ‫أ‬:‫وى‬ ‫ا‬ ‫ﺕ‬ ‫آ‬ ‫ا‬ ‫أو‬ ‫ل‬ ‫ا‬ ‫ء‬ ‫أﺙ‬ ‫ا‬ ‫رذاذ‬ ‫ل‬ ‫وى‬ ‫ا‬ ‫ﺕ‬‫ﺏ‬‫ا‬ ‫و‬ ‫ﺙ‬ ‫ب‬ ‫ﺵ‬ ‫رذاذ‬ ‫ا‬ ‫و‬ ‫ا‬ ‫أو‬ ‫ا‬‫أن‬ ‫وب‬ ‫ﺏ‬ ‫ﺏ‬ ‫ا‬ ‫ص‬ ‫ﺵ‬‫آ‬ ‫م‬ ‫ﺏ‬ ‫اض‬ ‫ا‬ ‫ر‬ ‫وى‬ ‫ا‬ ‫ة‬ ‫وى‬ ‫ا‬٥-٧‫ر‬ ‫ا‬ ‫ا‬ ‫أو‬ ‫ت‬ ‫وا‬ ‫ﺹ‬ ‫ا‬ ‫ا‬ ‫اآ‬ ‫و‬ ‫ارس‬ ‫ﺏ‬ ‫ﺏ‬ ‫وﺕ‬ ‫اض‬ ‫ا‬ ‫ر‬ ‫ﺏ‬ ‫م‬ ‫ا‬. ‫اض‬ ‫ا‬:‫ا‬ ‫ارة‬ ‫ع‬ ‫ارﺕ‬‫ة‬‫ا‬ ‫ن‬ ‫وا‬ ‫ف‬ ‫ﺝ‬ ‫ل‬‫وأ‬ ‫اع‬ ‫وﺹ‬ ‫ﺏ‬ ‫ورﺵ‬‫ﺏ‬‫ق‬ ‫ره‬ ‫ا‬ ‫ر‬ ‫وا‬ ‫ﺹ‬ ‫وا‬ ‫ت‬ ‫ا‬ ‫ز‬ ‫ﺏ‬ ‫ت‬ ‫اﺏ‬ ‫وا‬)‫ل‬ ‫إ‬-‫ء‬-‫ا‬ ‫ان‬(‫ل‬ ‫ا‬ ‫ﺏ‬ ‫ﺹ‬. ‫ﺏ‬ ‫ﺏ‬ ‫ﺹ‬ ‫ا‬ ‫ت‬ ‫و‬‫ا‬‫وث‬ ‫ا‬‫ا‬ ‫ا‬ ‫ر‬ ‫ه‬ ‫ﺕ‬ ‫و‬ ‫ف‬ ‫وﺝ‬ ‫ي‬ ‫رﺉ‬ ‫ب‬ ‫ا‬‫ﺹ‬ ‫ا‬‫ا‬ ‫ص‬ ‫ﺵ‬ ‫ا‬ ‫ﺏ‬ ‫ن‬‫اض‬ ‫أ‬‫و‬‫ة‬ ‫ا‬ ‫ا‬ ‫دي‬.
  10. 10. ‫آ‬‫ا‬ ‫ا‬ ‫اض‬ ‫أﻡ‬ ‫ﻡ‬ ‫ﻡ‬ ‫ا‬ ‫أو‬-‫ا‬‫ر‬ ‫ــ‬ ١-‫ي‬ ‫ا‬ ‫ن‬ ‫اﺉ‬ ‫ﺝ‬ ‫ا‬ ‫ا‬ ‫ﺕ‬ ‫ﺕ‬. ٢-‫ر‬ ‫أ‬ ‫ث‬ ‫ي‬ ‫ا‬ ‫ﺏ‬ ‫زة‬ ‫ا‬ ‫ت‬ ‫وﺏ‬ ‫ا‬ ‫آ‬ ‫آ‬ ‫ﺏ‬ ‫وا‬ ‫وا‬ ‫ز‬ ‫ﺏ‬ ‫ا‬ ‫ة‬ ‫ا‬‫أﺹ‬ ‫ا‬ ‫أﺹ‬ ‫ا‬ ‫أ‬ ‫رة‬ ‫ا‬ ‫وس‬ ‫ا‬ ‫ﺕ‬ ‫ﺝ‬. ٣-‫ا‬ ‫ا‬ ‫ت‬ ‫وﺝ‬ ‫ﺉ‬ ‫ا‬ ‫ا‬Inactivated vaccines. ‫ت‬ ‫ا‬Vaccines:‫ا‬ ‫ت‬ ‫وﺏ‬ ‫ا‬ ‫ات‬ ‫ه‬‫ت‬ ‫ﺉ‬‫أ‬ ‫م‬ ‫وﺕ‬"Naturally weak‫أو‬Artificially attenuated‫ر‬ ‫وأ‬Virulent"‫أو‬""Inactivated. ‫ت‬ ‫ا‬ ‫اع‬ ‫أ‬:‫ه‬ ‫رﺉ‬ ‫اع‬ ‫أ‬ ‫ﺙ‬ ‫ﺙ‬ ‫ا‬ ‫ت‬ ‫ا‬ ‫ﺕ‬: ١-‫ا‬ ‫ت‬ ‫ا‬Live vaccines. ٢-‫ا‬ ‫ت‬ ‫ا‬Inactivated vaccines. ٣-‫ﺹ‬ ‫ا‬ ‫ت‬ ‫ا‬vaccinesSpecial. ‫أو‬-‫ا‬ ‫ت‬ ‫ا‬Live vaccines ١-‫ت‬Naturally weak vaccines:‫ﺕ‬‫وب‬ ‫ي‬‫ﺏ‬‫ت‬ ‫آ‬ ‫ا‬”‫ب‬ ‫ه‬١‫ة‬ ‫و‬ ‫ﺕ‬ ‫وا‬F‫ـ‬ ‫وا‬ ‫وا‬ND 6/10‫ﺏ‬ ‫وا‬“‫و‬ ‫ا‬ ‫ﺏ‬ ‫ه‬ ‫وس‬ ‫ا‬ ‫ح‬ ‫وا‬ Herpes virus of turkey = HVT‫ر‬ ‫ض‬ ‫م‬ ‫ا‬. ٢-‫ﻡ‬ ‫ت‬Live attenuated or modified live vaccines:‫ا‬ ‫ﺕ‬ ‫وب‬ ‫ي‬ ‫ﺕ‬ ‫ح‬H120‫و‬H52‫ي‬ ‫ا‬ ‫ا‬ ‫ب‬ ‫ا‬IB‫ك‬ ‫ر‬ ‫ا‬ ‫ح‬ ‫و‬ ‫آ‬ ‫ا‬ ‫روف‬ ‫ا‬ ‫ح‬ ‫و‬ Laryngeovac‫ي‬ ‫ا‬ ‫اﺉ‬ ‫ا‬ ‫وا‬ ‫ة‬ ‫ا‬ ‫ب‬ ‫أ‬. ٣-‫ری‬ ‫ت‬Virulent:‫ا‬ ‫ن‬ ‫ا‬ ‫م‬ ‫وﺕ‬ ‫ا‬ ‫ﺕ‬ ‫ﺏ‬ ‫وب‬ ‫ي‬ ‫ﺕ‬Safe period‫أو‬ ‫ض‬ ‫ﺏ‬ ‫ﺏ‬ ‫ﺹ‬ ‫ﺏ‬ ‫ا‬Period of Insusceptibility‫أ‬ ‫و‬: -‫ﺉ‬ ‫ﺏ‬ ‫ا‬ ‫ش‬ ‫رﺕ‬ ‫ا‬ ‫ح‬‫ج‬ ‫ا‬:‫ا‬ ‫ن‬ ‫ا‬Safe period‫و‬ ‫ﺉ‬ ‫ﺏ‬ ‫ا‬ ‫ش‬ ‫رﺕ‬‫أ‬٧‫ﺏ‬ ‫أ‬"‫ة‬ ‫ﺏ‬ ‫ﺹ‬ ‫ﺏ‬ ‫ا‬Period of Insusceptibility"١٥‫أ‬"‫وي‬ ‫ا‬ ‫ا‬ ‫ا‬ ‫وس‬ ‫ا‬ ‫ل‬ ‫ه‬ ‫ﺏ‬ ‫ا‬ ‫ﺝ‬ ‫أ‬ ‫ا‬"‫وﺕ‬‫م‬١٠-١١‫أ‬‫ح‬ ‫ا‬ ‫ع‬‫ا‬‫ري‬. -‫ا‬ ‫و‬ ‫ا‬ ‫ي‬ ‫ا‬ ‫ب‬ ‫ا‬ ‫ح‬:‫ن‬ ‫ا‬Safe period‫ﺏ‬ ‫أ‬ ‫و‬ ‫و‬ ‫ا‬ ‫ي‬ ‫ا‬ ‫ب‬٤٠‫م‬ "‫ﺏ‬ ‫ﺹ‬ ‫ﺏ‬ ‫ا‬ ‫ة‬Period of Insusceptibility"‫وﺕ‬ ‫ﺉ‬ ‫ا‬ ‫و‬‫و‬ ‫ا‬ ‫ﺕ‬ ‫م‬Priming ٧٠-٨٠‫وا‬ ‫م‬Boostering‫ة‬ ‫ﺏ‬٦٠-٧٠‫و‬ ‫ا‬ ‫م‬. ٢-‫ﻡ‬ ‫ا‬ ‫ت‬ ‫ا‬Inactivated vaccines ‫ي‬ ‫ﺕ‬‫ا‬‫م‬ ‫ي‬ ‫ﺕ‬ ‫أو‬ ‫ﺕ‬ ‫ﺏ‬ ‫وب‬‫ﺏ‬‫أن‬ ‫ا‬ ‫ا‬ ‫ر‬ ‫ا‬ ‫ا‬ ‫ك‬ ‫وه‬ ‫ﺕ‬ ‫ﺏ‬ ‫ا‬ ‫ت‬ ‫ا‬ ‫ه‬‫وه‬: ‫أو‬-‫ﻡ‬ ‫ا‬ ‫ت‬ ‫ا‬ ‫ج‬ ‫ت‬ ‫وﺏ‬ ‫ا‬ ‫ﺕ‬ ‫ق‬ ١-‫اري‬ ‫ا‬ ‫ا‬Thermal Inactivation.٢-‫ﺵ‬ ‫ا‬ ‫ا‬Inactivation by Irradiation. ٣-‫ﺉ‬ ‫ا‬ ‫ا‬Chemical Inactivation -‫ل‬ ‫ا‬Phenol:‫آ‬ ‫ﺏ‬ ‫ﺏ‬ ‫ا‬ ‫م‬ ‫أ‬٠ ٠٤%‫و‬‫ة‬ ‫ا‬ ‫ﺏ‬ ‫م‬. -‫ر‬ ‫ا‬Formalin:‫آ‬ ‫ﺏ‬ ‫م‬٠ ٠٣%‫و‬ ‫ام‬ ‫ا‬ ‫ﺵ‬ ‫ا‬ ‫وه‬‫ا‬‫ا‬ ‫ﺵ‬ ‫ﺕ‬ ‫ث‬ ‫دة‬ ‫ز‬ ‫ل‬ ‫دة‬ ‫ﺝ‬ ‫و‬ ‫ا‬ ‫وب‬ ‫ا‬ ‫رة‬‫ة‬ ‫آ‬ ‫ر‬ ‫ﺙ‬ ‫د‬ ‫ة‬ ‫آ‬ ‫ك‬ ‫ض‬ ‫أ‬ ‫ل‬‫و‬‫ﺏ‬‫أ‬ ‫ﺉ‬ ‫ﺕ‬Fragmentation‫م‬ ‫ا‬ ‫وﺝ‬ ‫و‬ ‫ا‬ ‫رة‬ ‫ا‬ ‫ة‬ ‫ﺏ‬ ‫ﺙ‬ ‫ﺕ‬ ‫ف‬ ‫ا‬ ‫ت‬ ‫وﺏ‬ ‫ة‬ ‫آ‬ ‫ل‬ ‫ا‬ ‫ءة‬ ‫آ‬ ‫أآ‬ ‫ر‬. -‫ن‬ ‫آ‬ ‫وﺏ‬ ‫ﺏ‬ ‫ا‬Beta-propriolactone:‫ﺉ‬ ‫ﺕ‬Fragmentation‫ت‬ ‫وﺏ‬ ‫ﺏ‬‫ﺕ‬ ‫ف‬ ‫ا‬ ‫أﺙ‬ ‫أن‬ ‫و‬Carcinogenic effect.
  11. 11. -‫أ‬ ‫أ‬ ‫ي‬ ‫ﺏ‬Binary ethylene Amine:‫دة‬‫ذ‬‫ات‬‫وب‬ ‫ﺉ‬ ‫ﺕ‬ ‫و‬ ‫ءة‬ ‫وآ‬ ‫دة‬ ‫ﺝ‬ ‫ف‬ ‫ا‬Fragmentation‫ﺝ‬ ‫ا‬ ‫ا‬ ‫ع‬ ‫أرﺕ‬ ‫و‬ ‫ﺕ‬. -‫ت‬ ‫ﺏ‬ ‫وآ‬ ‫ﺏ‬ ‫أ‬ ‫داي‬Diethylpyrocarbonate:‫و‬ ‫وس‬ ‫ا‬ ‫ﺕ‬ ‫وذ‬ ‫ت‬ ‫و‬ ‫ا‬ ‫ﺉ‬ ‫ا‬ ‫ق‬ ‫ا‬ ‫أ‬ ‫ا‬ ‫ز‬ ‫ة‬ ‫ا‬ ‫ا‬ ‫اآ‬ ‫ا‬ ‫آ‬ ‫ﺕ‬. -‫ر‬ ‫آ‬ ‫ا‬ ‫ا‬Benzalcolium chloride:‫ﺉ‬ ‫ﺕ‬ ‫أي‬ ‫و‬ ‫ام‬ ‫ا‬ ‫ن‬ ‫ا‬ ‫أ‬ ‫آ‬ ‫وا‬ ‫آ‬ ‫ا‬ ‫ه‬ Fragmentation‫ا‬ ‫ﺏ‬ ‫ا‬ ‫اﺝ‬ ‫ا‬ ‫آ‬ ‫ﺹ‬ ‫وﺕ‬ ‫ا‬ ‫رة‬ ‫ا‬ ‫أﺙ‬ ‫أي‬ ‫و‬ ‫ﺕ‬ ‫ف‬ ‫ا‬ ‫ت‬ ‫وﺏ‬ ‫ﺝ‬ ‫ا‬ ‫ا‬ ‫ع‬ ‫أرﺕ‬ ‫ا‬ ‫ا‬ ‫و‬ ‫ت‬ ‫ا‬ ‫ﺹ‬. ‫ﺙ‬-‫ح‬ ‫ا‬ ‫ات‬ ‫ﻡ‬Adjuvants ‫ا‬ ‫ح‬ ‫ا‬ ‫ﺕ‬ ‫ﺝ‬ ‫ﺏ‬ ‫أو‬ ‫ﺉ‬ ‫آ‬ ‫اد‬ ‫ه‬‫ﺕ‬ ‫ض‬ ‫ﺏ‬ ‫أو‬‫ا‬‫ﺏ‬‫ا‬‫دة‬ ‫ا‬ ‫ن‬ ‫أن‬ ‫دون‬ ‫آ‬ ‫أﺵ‬ ‫و‬ ‫أ‬ ‫أﺙ‬ ‫أي‬Adjuvant‫ﺕ‬ ‫ا‬ ‫ا‬Adjuvare‫وﺕ‬Help or aid‫ا‬ ‫ﺏ‬ ‫ﺹ‬ ‫أن‬ ‫ﺏ‬ ‫ن‬ ‫را‬ ‫ا‬١٩٢٦‫م‬. ‫وأآ‬‫ﺏ‬ ‫ت‬ ‫ا‬ ‫ا‬‫ت‬ ‫د‬ ‫ﺏ‬ ‫ت‬ ‫ا‬ ‫ة‬ ‫ت‬ ‫أ‬ ‫ك‬ ‫ه‬ ‫أن‬ ‫ت‬ ‫ا‬ ‫ﺕ‬ ‫ت‬ ‫ا‬ ‫ح‬ ‫ا‬ ‫ة‬ ‫ض‬ ‫أ‬ ‫وث‬ ‫ا‬ ‫ح‬ ‫ا‬ ‫وة‬ ‫ﺏ‬ ‫أآ‬ ‫ا‬ ‫أه‬ ‫و‬ ‫ح‬ ‫ﺏ‬ ‫ت‬ ‫ﺙ‬ ‫ﺏ‬ ‫ث‬ ‫ﺕ‬ ‫د‬ ‫ﺝ‬ ‫ذ‬ ‫وا‬ ‫وأ‬ ‫ي‬ ‫وأ‬ ‫ـ‬ ‫ا‬ ‫ﺕ‬ ‫ة‬ ‫ه‬ ‫ا‬ ‫ه‬ ‫ا‬ ‫وأ‬Dirty little secret‫أ‬ ‫أي‬‫ﺵ‬ ‫ﺏ‬ ‫ﺵ‬ ‫ب‬ ‫آ‬‫ا‬ ‫آ‬ ‫أن‬ ‫ا‬ ‫أآ‬ ‫ا‬ ‫را‬ ‫وﺏ‬ ‫ﺕ‬ ‫آ‬ ‫ﺹ‬ ‫ﺉ‬ ‫آ‬ ‫ت‬ ‫آ‬ ‫أ‬ ‫ﺕ‬ ‫ت‬ ‫ﺙ‬ ‫ا‬‫دي‬‫ح‬ ‫ا‬ ‫ات‬ ‫ا‬ ‫ا‬ ‫وأ‬ ‫ت‬ ‫وﺝ‬ ‫أذا‬ ‫ح‬ ‫ا‬ ‫ة‬ ‫دة‬ ‫دا‬ ‫إ‬ ‫ح‬ ‫ا‬ ‫ر‬ ‫ﺕ‬ ‫ء‬ ‫اﺏ‬ ‫ﺕ‬ ‫ا‬ ‫ه‬ ‫ح‬ ‫ا‬ ‫ات‬ ‫اع‬ ‫أ‬ ‫وأﺏ‬‫ا‬. ‫ا‬ ‫ا‬ ‫ﺏ‬ ‫ا‬ ‫ز‬ ‫ا‬ ‫وﺕ‬ ‫ﺝ‬ ‫ﺕ‬ ‫أن‬ ‫ده‬ ‫ح‬ ‫ا‬ ‫ات‬ ‫م‬ ‫وﺕ‬Antigen Driven‫أن‬ ‫أي‬ ‫ا‬ ‫ز‬ ‫ا‬‫ا‬‫ا‬ ‫د‬ ‫ﺝ‬‫و‬‫ا‬ ‫ﺏ‬ ‫ا‬‫ا‬‫ا‬ ‫ر‬ ‫ﺕ‬ ‫ا‬ ‫ة‬‫ا‬ ‫ﺏ‬ ‫ا‬ ‫ة‬ ‫وﺏ‬ ‫ﺏ‬ ‫ء‬ ‫ﺏ‬. Mode of actionAdjuvantTypes Slow release of antigen depot. Aluminum phosphate،aluminum hydroxideand alum aluminum potassium sulfate Aluminum salts Slow release of antigen depot. Freund's incompleteWater in oil emulsion Slow release of antigendepot + Macrophagestimulation. Freund's complete Mixed adjuvants"Water in oil emulsion+killed mycobacterium Macrophagestimulation Corynebacteriumparvum, Coryn. granulosium, Bacillus-Calmette-Guerin، Bordetella pertussis Bacterial fractions Stimulate antigenprocessing Lanolin،Saponin،sodium alginate، Lysolecithin, vitaminA, Vitamin E. Surface active agents Macrophagestimulation.Acemannan, glucans،dextran sulphateComplexcarbohydrates Enhances CMI-Lymphokines production andsuppressor cellfunction, stimulates phagocytic activities of macrophages and heterophils. Similar to the thymichormone thymopoietinand stimulates T- lymphocytedifferentiation andtheir response toantigens. Levamisole Enhance Ab formationand immune reactivityby promotinginterferon release. Lipopolysaccharides Muramyl dipeptide Bacterial endotoxins ‫ﺙ‬-‫ﻡ‬ ‫ا‬ ‫ح‬ ‫ا‬ ‫آ‬ ‫ا‬Antigenic concentration ‫ﺉ‬ ‫ا‬ ‫ءﺕ‬ ‫آ‬ ‫داد‬ ‫ﺕ‬ ‫وﺏ‬ ‫ا‬ ‫ﺏ‬ ‫ا‬ ‫زادت‬ ‫زاد‬ ‫آ‬. ‫راﺏ‬-‫ﻡ‬ ‫ا‬ ‫ح‬ ‫ا‬ ‫آ‬Mechanism of action ‫ق‬ ‫أن‬‫ا‬ ‫ت‬ ‫وا‬ ‫اﺏ‬ ‫ا‬ ‫ﺏ‬ ‫أن‬ ‫ﺏ‬ ‫ا‬ ‫ح‬ ‫ا‬‫و‬ ‫آ‬ ‫وا‬ ‫ﺝ‬‫ه‬:
  12. 12. ١-‫م‬ ‫ا‬ ‫دا‬ ‫ا‬ ‫ت‬ ‫ﺉ‬ ‫ا‬ ‫آ‬Homothermous‫ا‬ ‫ارة‬ ‫ا‬ ‫درﺝ‬ ‫ول‬ ‫ا‬ ‫ا‬ ‫ارة‬ ‫درﺝ‬ ‫ن‬surface temperature‫ا‬ ‫ا‬ ‫ارة‬ ‫ا‬ ‫درﺝ‬ ‫ه‬ ‫وا‬core temperature‫أ‬ ‫ن‬ ‫ﺕ‬ ‫ا‬ ‫ا‬ ‫ارة‬ ‫وا‬٢‫ا‬ ‫ارة‬ ‫ا‬ ‫درﺝ‬. ٢-‫درﺝ‬‫ا‬‫ا‬ ‫ارة‬‫ر‬Avian surface temperature٤٢‫ا‬ ‫ا‬ ‫ارة‬ ‫درﺝ‬ ‫ن‬ ‫ﺕ‬ ‫و‬ ‫درﺝ‬ ‫ر‬ ‫ا‬Avian core temperature٤٤‫درﺝ‬. ٣-‫ﺵ‬ ‫ب‬ ‫ا‬ ‫وث‬ ‫دي‬ ‫و‬ ‫ا‬ ‫أو‬ ‫ا‬ ‫ﺕ‬ ‫ا‬ ‫ﺕ‬ ‫ا‬ ‫ت‬ ‫ا‬ ‫ﺝ‬Local inflammation‫ح‬ ‫اﺉ‬ ‫ا‬ ‫ﺏ‬Adjuvant. ٤-‫ا‬ ‫ا‬ ‫ارة‬ ‫ا‬ ‫درﺝ‬ ‫ر‬ ‫ا‬ ‫دي‬ ‫ا‬ ‫ﺏ‬ ‫ا‬ ‫ب‬ ‫ا‬٢‫ة‬ ‫ا‬ ‫اض‬ ‫ﺕ‬ ‫وذ‬ ‫درﺝ‬ ‫ب‬Cardinal signs of Inflammation. ٥-‫ﺏ‬ ‫اوح‬ ‫ﺕ‬ ‫ت‬ ‫ا‬ ‫ر‬ ‫أ‬ ‫درﺝ‬٤٤-٤٦‫درﺝ‬‫ا‬ ‫ح‬ ‫ا‬ ‫ﺏ‬ ‫ا‬ ‫ارة‬ ‫ا‬ ‫درﺝ‬ ‫أن‬ ‫ب‬ ‫و‬٤٦ ‫درﺝ‬"٤٤‫دا‬ ‫ارة‬ ‫درﺝ‬+٢‫ا‬ ‫ب‬ ‫ا‬=٤٦‫أﺝ‬"‫ر‬ ‫أ‬ ‫رﺝ‬ ‫ا‬ ‫ا‬ ‫وي‬ ‫ﺕ‬ ‫وا‬ ‫ا‬ ‫ا‬ ‫ر‬ ‫ح‬ ‫و‬ ‫وا‬ ‫ا‬ ‫ا‬ ‫ﺕ‬ ‫ت‬ ‫ا‬‫ز‬ ‫ا‬ ‫ا‬ ‫أ‬ ‫وﺕ‬ ‫ح‬ ‫وﺏ‬ ‫ا‬ ‫أو‬ ‫ﺉ‬ ‫ا‬. ٦-‫ا‬ ‫ح‬ ‫ا‬ ‫ة‬ ‫ا‬ ‫ا‬ ‫ة‬ ‫ا‬٣‫ت‬: -‫ا‬‫رﺝ‬ ‫ا‬‫ا‬Oily layer:‫ﺏ‬ ‫اوح‬ ‫ﺕ‬ ‫ة‬ ‫وب‬ ‫وﺕ‬ ‫ح‬ ‫ا‬ ‫ﺏ‬ ‫ص‬ ‫ز‬ ‫ن‬ ‫وﺕ‬٦-٧‫ح‬ ‫ا‬ ‫م‬ ‫م‬. -‫ا‬‫ا‬‫و‬ ‫ا‬Emulsion layer:‫ن‬ ‫وﺕ‬‫و‬”‫ز‬‫ﺝ‬ ‫ح‬ ‫ا‬‫ﺏ‬‫ء‬“‫اد‬ ‫ا‬ ‫ﺏ‬ ‫ا‬ ‫ﺏ‬ Emulsifiers‫ا‬ ‫وب‬ ‫وﺕ‬٥-٦‫ح‬ ‫ا‬ ‫م‬ ‫م‬. -‫وﺏ‬ ‫ا‬ ‫ﺉ‬ ‫ا‬ ‫ا‬Watery or viral layer:‫وه‬‫ﺉ‬‫ا‬ ‫وب‬ ‫وﺕ‬٣‫ح‬ ‫ا‬ ‫م‬. ‫ا‬ ‫أن‬‫ز‬ ‫ة‬ ‫ﺏ‬ ‫ا‬ ‫ز‬ ‫ا‬ ‫ﺕ‬ ‫أ‬ ‫ا‬ ‫ح‬=٦ ٥+٥ ٥+٣=١٥‫م‬.
  13. 13. ‫ﻡ‬ ‫ا‬ ‫ت‬ ‫وا‬ ‫ا‬ ‫ت‬ ‫ا‬ ‫ﺏ‬ ‫ر‬ ‫ﻡ‬ ‫ر‬ ‫ا‬ ‫أو‬‫ا‬ ‫ح‬ ‫ا‬‫ﻡ‬ ‫ا‬ ‫ح‬ ‫ا‬ ‫ا‬ ‫آ‬ ‫ا‬LowHigh ‫ا‬‫ﺏ‬"٢-٣‫م‬"‫ﺏ‬"‫ا‬ ‫أ‬ ‫ﺏ‬" ‫ا‬ ‫ة‬ ‫ﻡ‬ ‫ا‬ ‫ج‬ ‫أ‬Adjuvant‫ج‬‫ج‬ ‫ا‬ ‫ﺏ‬ ‫ا‬IgG, IgM & IgAIgG ‫ا‬ ‫ا‬ ‫ی‬ ‫ا‬ ‫ﺏ‬ ‫ا‬ ‫ا‬ ‫ی‬ ‫ا‬CD 4+ and CD 8+CD 4+ ‫أ‬‫ون‬ ‫ا‬ ‫ج‬ ‫ء‬ ‫ﺏ‬ ‫ا‬ ‫ا‬ ‫ﻡ‬ ‫ا‬Emergency‫ل‬‫ل‬ ‫ی‬ ‫ا‬ ‫در‬ ‫اوة‬ ‫ا‬ ‫دة‬ ‫أ‬ ‫أﻡ‬Reversion ‫ا‬ ‫ا‬ ‫رد‬ ‫ﻡ‬ ‫ا‬ ‫ﺏ‬ ‫دل‬ ‫ا‬ ‫ح‬ ‫ا‬ ‫ث‬ ‫ﺕ‬ ‫أﻡ‬ ‫ﻡ‬ ‫ا‬ ‫ا‬‫در‬‫ﺝ‬‫رض‬ ‫ﺕ‬ ‫د‬ ‫ﺝ‬ ‫ا‬‫ﺉ‬ ‫ﺵ‬‫رض‬ ‫ﺕ‬ ‫د‬ ‫وﺝ‬ ‫م‬ ‫ا‬ ‫ﺝ‬ ‫ا‬ ‫ا‬‫دي‬Individual‫وﺝ‬Mass‫دي‬Individual‫وﺏ‬. ‫دی‬ ‫ا‬ ‫ا‬‫ر‬ ‫ﺙ‬-‫ا‬ ‫ت‬ ‫ا‬Special vaccines ‫ت‬ ‫ه‬‫ا‬ ‫ق‬ ‫ﺏ‬ ‫ﺝ‬ ‫ﺏ‬ ‫وﺕ‬ ‫وراﺙ‬ ‫ﺕ‬‫وﺕ‬ ‫راﺙ‬ ‫ا‬: -‫ا‬ ‫أو‬ ‫اآ‬ ‫ا‬ ‫ت‬ ‫ا‬Recombinant vaccines: ‫و‬‫ا‬ ‫ا‬ ‫دات‬ ‫ا‬ ‫ﺕ‬Epitopes‫و‬ ‫ح‬ ‫ف‬ ‫ا‬ ‫وب‬‫ا‬Guest‫و‬‫ء‬ ‫ا‬ ‫ا‬ ‫ه‬ ‫م‬ ‫ا‬‫و‬‫ﺏ‬ ‫ص‬ ‫ا‬ ‫م‬ ‫ا‬ ‫راﺙ‬ ‫ا‬ ‫ا‬ ‫ﺉ‬ ‫ﺏ‬ ‫وﺹ‬ ‫د‬‫و‬ ‫ﺕ‬ ‫ا‬ ‫أو‬ ‫ري‬ ‫ا‬ ‫وس‬ ‫أ‬ ‫وب‬‫ﺉ‬ ‫ا‬ Host‫و‬ ‫ﺏ‬ ‫ﺹ‬ ‫ا‬ ‫ا‬ ‫ا‬ ‫دات‬ ‫ا‬ ‫ﺉ‬ ‫ا‬ ‫م‬ ‫ﺝ‬ ‫و‬‫ﺕ‬ ‫آ‬‫و‬ ‫ا‬ ‫وس‬ ‫ﺏ‬ ‫ﺹ‬ ‫ا‬ ‫ﺙ‬ ‫ا‬ ‫ا‬ ‫أ‬‫ت‬ ‫ا‬ ‫ع‬ ‫ا‬ ‫ا‬ ‫ه‬ ‫ﺝ‬ ‫و‬‫آ‬‫ﺕ‬: -‫ا‬ ‫ح‬ ‫ا‬‫ري‬ ‫ا‬ ‫وس‬ ‫ر‬ ‫ا‬ ‫ا‬ ‫أ‬ ‫وس‬ ‫اآ‬‫و‬‫ﺕ‬ ‫ا‬ ‫ر‬ ‫ا‬ ‫ا‬ ‫أ‬ ‫وس‬ ‫اآ‬ ‫ا‬ ‫ح‬ ‫ا‬ ‫ري‬ ‫ا‬ ‫ا‬ ‫ﺕ‬ ‫ءة‬ ‫آ‬ ‫أ‬ ‫ﺕ‬ ‫ا‬ ‫ا‬ ‫ت‬ ‫ا‬ ‫أن‬ ‫رب‬ ‫ا‬ ‫وأﺙ‬‫و‬‫رو‬ ‫ا‬ ‫وس‬ ‫اآ‬ ‫ا‬ ‫ح‬ ‫ا‬ ‫ر‬ ‫ا‬ ‫وس‬. -‫ا‬‫ی‬ ‫ا‬ ‫ت‬Sub-unit vaccines:‫ا‬ ‫دات‬ ‫ا‬ ‫ﺕ‬ ‫و‬Epitopes‫ح‬ ‫ا‬ ‫ف‬ ‫ا‬ ‫وب‬ ‫ي‬ ‫ا‬ ‫وس‬ ‫ا‬ ‫ح‬ ‫أ‬ ‫و‬ ‫ح‬ ‫آ‬ ‫ة‬ ‫ﺵ‬ ‫م‬ ‫و‬ ‫ﺙ‬ ‫م‬ ‫ا‬ ‫ء‬ ‫ا‬ ‫ا‬ ‫ه‬ ‫و‬-‫ن‬ ‫ا‬ ‫ﺏ‬. -‫ة‬ ‫ا‬ ‫ت‬ ‫ا‬Anti-idiotypic vaccines:‫و‬‫دة‬ ‫م‬ ‫أﺝ‬ ‫ج‬ ‫آ‬ ‫وس‬ ‫ا‬ ‫م‬"١"‫د‬ ‫ﺙ‬ ‫دة‬ ‫ا‬ ‫م‬ ‫ﺝ‬ ‫ا‬ ‫ام‬ ‫أ‬"١"‫دة‬ ‫أﺝ‬ ‫ي‬ ‫أ‬ ‫ة‬ ‫ت‬ ‫آ‬"٢"‫وس‬ ‫ا‬ ‫ﺝ‬ ‫ر‬ ‫ﺕ‬ ‫وا‬ ‫وة‬ ‫ا‬ ‫دة‬ ‫ا‬ ‫م‬ ‫ﺝ‬ ‫ا‬ ‫م‬ ‫ﺕ‬ ‫ﺙ‬ ‫ﺹ‬ ‫ا‬"٢"‫ﺕ‬ ‫ت‬ ‫ا‬ ‫ع‬ ‫ا‬ ‫ا‬ ‫وه‬ ‫ح‬ ‫آ‬‫وأ‬ ‫ز‬ ‫ا‬ ‫ض‬ ‫م‬‫آ‬ ‫ا‬. -‫ا‬ ‫ت‬ ‫ا‬Synthetic vaccines:‫و‬‫ا‬ ‫دات‬ ‫ي‬ ‫آ‬ ‫ا‬ ‫ﺏ‬ ‫ا‬Epitopes‫ف‬ ‫ا‬ ‫وب‬ ‫ا‬ ‫ح‬ ‫أ‬ ‫و‬ ‫ﺹ‬ ‫ا‬ ‫وب‬ ‫ا‬ ‫ح‬ ‫آ‬ ‫ا‬ ‫وأ‬ ‫ﺕ‬ ‫ﺙ‬ ‫ح‬ ‫ا‬‫ي‬ ‫ا‬ ‫وس‬-‫ن‬ ‫ا‬ ‫ﺏ‬. ‫ت‬ ‫ا‬ ‫ﺏ‬ ‫ا‬ ‫أ‬-‫ی‬ ‫ا‬ ‫ا‬ ‫ﺏ‬ ‫ا‬mediated Immunity-Cell ‫ا‬ ‫ا‬ ‫ﺏ‬ ‫ا‬ ‫ﺕ‬‫ﺏ‬‫ا‬-‫ﺕ‬ ‫وا‬ ‫ﺕ‬‫ﺏ‬ ‫م‬‫ا‬‫ت‬ ‫آ‬ ‫ا‬ ‫ز‬Lymphokines‫ﺕ‬ ‫ﺏ‬ ‫و‬ ‫آ‬ ‫ا‬ ‫وﺕ‬ ‫ك‬ ‫ﺕ‬ ‫دي‬‫وﺕ‬ ‫ا‬ ‫م‬ ‫ﺝ‬ ‫ا‬ ‫ﺝ‬ ‫ﺏ‬ ‫م‬ ‫ج‬-‫ة‬ ‫ا‬ ‫ﺕ‬T.helper cell.
  14. 14. ‫ا‬ ‫ا‬ ‫رة‬ ‫ا‬ ‫و‬‫ﺕ‬‫ا‬ ‫ه‬ ‫ا‬-‫ا‬ ‫ﺕ‬T-cytotoxic‫ا‬ ‫ﺝ‬ ‫ﺕ‬ ‫وا‬ ‫ا‬ ‫ى‬ ‫وا‬-‫ة‬ ‫اآ‬ ‫ا‬ ‫ﺕ‬Memory T-cells‫ا‬ ‫و‬ ‫ا‬‫ا‬ ‫ض‬ ‫ﺕ‬ ‫ا‬ ‫ا‬ ‫ا‬ ‫ﺏ‬ ‫ى‬ ‫أ‬ ‫ة‬ ‫ا‬. ‫ع‬ ‫ا‬ ‫ا‬ ‫ا‬ ‫وﺕ‬‫ا‬‫ﺹ‬ ‫رة‬ ‫وﺏ‬ ‫اض‬ ‫ا‬ ‫ت‬‫ت‬ ‫ا‬ ‫ﺕ‬‫دا‬ ‫ﺕ‬ ‫ا‬ ‫ا‬Intercellular‫ا‬ ‫ا‬ ‫وا‬ ‫ت‬ ‫ا‬ ‫وآ‬‫رك‬ ‫و‬ ‫ا‬ ‫ا‬ ‫وﺕ‬ ‫ﺉ‬ ‫ل‬ ‫ا‬ ‫ا‬ ‫إ‬ ‫ﺏ‬ ‫ا‬ ‫ا‬-‫ﺕ‬ ‫ا‬ ‫ا‬ ‫ى‬ ‫أ‬ ‫ج‬ ‫و‬ ‫آ‬ ‫وا‬ ‫ﺕ‬killer cell‫ا‬ ‫ﺕ‬ ‫ا‬ ‫وا‬Natural killer cell‫اة‬ ‫ا‬ ‫ة‬ ‫و‬ ‫آ‬ ‫ا‬ ‫وا‬Monocytes. ‫ب‬-‫ا‬ ‫ا‬ ‫ﺏ‬ ‫ا‬mediated Immunity-Antibody ‫دة‬ ‫ا‬ ‫م‬ ‫ﺝ‬ ‫ا‬ ‫ﺕ‬Antibodies‫ﺏ‬ ‫ا‬‫ا‬‫ﺏ‬ ‫ﺝ‬Gama globulins‫ر‬ ‫ا‬ ‫ﺝ‬ ‫و‬‫ﺙ‬ ‫ﺙ‬ ‫ـ‬ ‫ا‬ ‫ه‬ ‫اع‬ ‫أ‬IgY‫ـ‬ ‫ا‬ ‫و‬IgM‫ـ‬ ‫وا‬IgA‫وا‬ ‫ح‬ ‫آ‬ ‫ﺏ‬ ‫ص‬ ‫د‬ ‫ﺝ‬ ‫أ‬ ‫وآ‬‫ا‬ ‫ا‬ ‫وﺕ‬‫ع‬ ‫ﺕ‬ ‫ﺙ‬ ‫ﺙ‬ ‫وه‬‫ﺏ‬ ‫ه‬ ‫ﺙ‬ ‫ﺕ‬‫ا‬: ١-‫ﺉ‬ ‫ا‬ ‫ا‬Humoral Immunity:‫وﺕ‬ ‫وي‬ ‫ا‬ ‫ﺉ‬ ‫وا‬ ‫م‬ ‫ا‬ ‫ه‬ ‫ه‬ ‫ﺙ‬ ‫ﺕ‬ ‫ن‬ ‫و‬ ‫ا‬ ‫ا‬ ‫ع‬ ‫ﺕ‬ ‫ه‬ ‫ـ‬ ‫ا‬ ‫ه‬ ‫دة‬ ‫ا‬ ‫م‬ ‫ﺝ‬ ‫ا‬ ‫د‬ ‫وﺝ‬IgM‫ـ‬ ‫ا‬ ‫و‬IgY. ٢-‫ا‬ ‫أو‬ ‫ا‬ ‫ا‬ocal or mucosal ImmunityL:‫ه‬ ‫ه‬ ‫ﺙ‬ ‫ﺕ‬ ‫ن‬ ‫و‬ ‫ا‬ ‫ا‬ ‫ع‬ ‫ﺕ‬ ‫وه‬ ‫ا‬ ‫ت‬ ‫و‬ ‫ا‬ ‫رأ‬ ‫و‬ ‫ت‬ ‫وﺏ‬ ‫ا‬ ‫ا‬ ‫ا‬ ‫وأه‬ ‫أآ‬ ‫ﺕ‬ ‫ا‬ ‫ا‬ ‫ة‬ ‫ﺝ‬ ‫ا‬ ‫ا‬ ‫ا‬ ‫د‬ ‫ز‬ ‫أن‬ ‫آ‬ ‫وا‬ ‫ي‬ ‫ا‬ ‫ا‬ ‫ب‬ ‫وا‬ ‫ا‬ ‫وا‬ ‫آ‬ ‫آ‬‫ت‬ ‫و‬ ‫ا‬ ‫ه‬ ‫ا‬ ‫ا‬ ‫ﺕ‬ ‫ا‬ ‫ا‬ ‫رة‬ ‫ة‬ ‫ـ‬ ‫ا‬ ‫ه‬ ‫ا‬ ‫ا‬ ‫ا‬ ‫ﺏ‬ ‫ي‬ ‫ا‬ ‫د‬ ‫ا‬ ‫وا‬IgA‫وب‬ ‫ا‬ ‫ق‬ ‫ا‬ ‫د‬ ‫ا‬ ‫ا‬ ‫ا‬ ‫ه‬ ‫م‬ ‫و‬ ‫ره‬ ‫ا‬ ‫ا‬ ‫آ‬ ‫ﺉ‬ ‫ا‬ ‫ا‬. ٣-‫ﻡ‬ ‫ا‬ ‫ا‬‫ا‬ ‫ا‬ ‫أو‬ ‫روﺙ‬ ‫ا‬Maternal or Passive Immunity:‫و‬ ‫ا‬ ‫ا‬ ‫ع‬ ‫ﺕ‬ ‫وه‬ ‫آ‬ ‫ا‬ ‫ﺕ‬ ‫وا‬ ‫ا‬ ‫ا‬ ‫ﺕ‬ ‫ا‬ ‫ﺝ‬ ‫ت‬ ‫ا‬ ‫دا‬ ‫ﺕ‬ ‫ا‬ ‫ا‬ ‫آ‬ ‫ء‬ ‫ﺝ‬ ‫ل‬ ‫اض‬ ‫ا‬ ‫ﺏ‬ ‫ا‬‫ا‬ ‫ﺏ‬ ‫ا‬ ‫ا‬ ‫ا‬ ‫ر‬ ‫وﺕ‬ ‫ه‬ ‫و‬ ‫ا‬ ‫ﺏ‬ ‫أ‬ ‫ﺙ‬ ‫ا‬٦٠% ‫ـ‬ ‫ا‬ ‫ه‬ ‫ﺝ‬ ‫ا‬ ‫ا‬ ‫ت‬ ‫ا‬ ‫ل‬ ‫ﺏ‬ ‫ﺕ‬ ‫ا‬ ‫دة‬ ‫ا‬ ‫م‬ ‫ﺝ‬ ‫وا‬ ‫ت‬ ‫ﺏ‬ ‫دة‬ ‫ﺝ‬ ‫ا‬ ‫ا‬IgY‫ـ‬ ‫وا‬ ‫ا‬IgA ‫ا‬.
  15. 15. ‫ا‬ ‫ا‬Passive Immunization ‫ة‬ ‫ه‬ ‫ا‬ ‫دة‬ ‫ا‬ ‫م‬ ‫ﺝ‬ ‫ا‬ ‫ض‬ ‫ﺏ‬ ‫ﺏ‬ ‫ا‬ ‫ر‬ ‫ا‬ ‫ء‬ ‫أ‬ ‫أي‬‫ن‬ ‫ا‬ ‫ا‬ ‫ه‬ ‫ل‬ ‫ا‬ ‫أ‬ ‫وﺏ‬١٩‫ن‬ ‫ا‬ ‫آ‬ ‫وآ‬ ‫اض‬ ‫ا‬ ‫ا‬ ‫ا‬ ‫ن‬ ‫و‬ ‫م‬ ‫ا‬ ‫ن‬ ‫و‬ ‫ﺉ‬ ‫د‬ ‫ت‬ ‫ون‬ ‫ﺙ‬ ‫اض‬ ‫ا‬ ‫ت‬ ‫ﺏ‬ ‫ل‬ ‫ا‬‫ن‬ ‫د‬ ‫ﺕ‬ ‫ﺏ‬ ‫آ‬ ‫ا‬ ‫ا‬ ‫آ‬ ‫ا‬ ‫ه‬ ‫ل‬‫اض‬ ‫أ‬‫ل‬ ‫ا‬ ‫م‬ ‫ا‬ ‫أ‬ ‫ض‬ ‫ا‬ ‫أﺹ‬ ‫أ‬ ‫ن‬ ‫ﺕ‬ ‫ﺝ‬ ‫اض‬ ‫ا‬ ‫ﺕ‬ ‫و‬ ‫ﺝ‬ ‫ا‬ ‫وه‬ ‫ا‬ ‫ارع‬ ‫ا‬ ‫ص‬ ‫ﺏ‬ ‫وﺕ‬ ‫ﺏ‬ ‫دة‬ ‫ا‬ ‫م‬ ‫ﺝ‬ ‫ا‬ ‫ﺕ‬ ‫ا‬ ‫ب‬: ١-‫ا‬‫وﺕ‬ ‫ﺕ‬ ‫ﺏ‬ ‫ا‬ ‫ة‬ ‫ﺕ‬ ‫دة‬ ‫ا‬ ‫م‬ ‫ﺝ‬. ٢-‫ض‬ ‫ا‬ ‫ر‬ ‫ﺕ‬ ‫ﺏ‬ ‫ﺹ‬ ‫ا‬ ‫ﺏ‬ ‫ﺕ‬ ‫ا‬ ‫ض‬ ‫ا‬ ‫د‬ ‫وﺝ‬ ‫ا‬ ‫دة‬ ‫ا‬ ‫م‬ ‫ﺝ‬ ‫ا‬‫ﺏ‬‫ض‬ ‫ﺕ‬ ‫إذا‬ ‫ه‬ ‫ﺝ‬ ‫دة‬ ‫م‬ ‫ﺝ‬ ‫ﺏ‬ ‫ا‬ ‫داء‬ ‫و‬ ‫آ‬ ‫ن‬ ‫أ‬‫وس‬ ‫ﺏ‬ ‫ﺕ‬ ‫ﺕ‬ ‫وا‬ ‫ا‬ ‫وس‬ ‫ة‬ ‫ض‬ ‫ﺏ‬ ‫ﺏ‬ ‫ﺹ‬ ‫ا‬ ‫ا‬ ‫ا‬ ‫ه‬ ‫ﺕ‬ ‫وﺏ‬ ‫د‬ ‫وﺕ‬. ٣-‫ﺏ‬ ‫ﺏ‬ ‫م‬ ‫ا‬ ‫ز‬ ‫ا‬‫د‬ ‫وﺝ‬ ‫م‬‫أ‬‫ﺏ‬‫ة‬ ‫ذاآ‬ ‫ن‬ ‫ﺕ‬ ‫ا‬. ‫ر‬ ‫ا‬ ‫ا‬ ‫ا‬ ‫ام‬ ‫أ‬ ‫ا‬ ‫ا‬ ‫م‬‫ا‬ ‫ء‬ ‫ﺏ‬ ‫وذ‬ ‫ج‬ ‫ﺝ‬ ‫ا‬ ‫رو‬ ‫ا‬ ‫ج‬ ‫و‬ ‫ا‬ ‫ا‬ ‫و‬ ‫ا‬ ‫ي‬ ‫ا‬ ‫ب‬ ‫ا‬ ‫ج‬ ‫واﺝ‬ ‫ا‬ ‫ﺕ‬ ‫ا‬ ‫وا‬ ‫ا‬ ‫ج‬ ‫ﺝ‬ ‫ا‬ ‫أو‬ ‫ا‬: ١-‫ا‬ ‫ا‬ ‫ي‬ ‫ا‬ ‫ا‬ ‫ب‬ ‫أ‬ ‫أو‬ ‫و‬ ‫ا‬ ‫ي‬ ‫ا‬ ‫ب‬ ‫ا‬ ‫ج‬ ‫دﺝ‬ ‫أو‬ ‫ﺏ‬ ‫ت‬ ‫أ‬ ‫ذ‬ ‫ا‬ ‫م‬ ‫ا‬‫ا‬ ‫ا‬ ‫ﺏ‬٠ ٥‫ة‬ ‫ﺉ‬٣‫ا‬ ‫ا‬ ‫ا‬ ‫وه‬ ‫م‬ ‫أ‬. ٢-‫ا‬ ‫ﺏ‬ ‫ا‬ ‫ا‬ ‫ا‬ ‫رو‬ ‫ا‬ ‫أو‬ ‫و‬ ‫ا‬ ‫ي‬ ‫ا‬ ‫ب‬ ‫ا‬ ‫ج‬ ‫دﺝ‬ ‫أو‬ ‫ﺏ‬ ‫ت‬ ‫أ‬ ‫ﺏ‬ ‫ذ‬ ‫ا‬ ‫ا‬ ٠ ٥‫ة‬ ‫ﺉ‬٣‫أﺙ‬ ‫ا‬ ‫وه‬ ‫م‬ ‫أ‬‫ا‬ ‫و‬. ‫ا‬ ‫ا‬ ‫اض‬ ‫أﻡ‬ ‫ﻡ‬ ‫ﻡ‬ ‫ا‬ ‫ن‬ ‫ا‬ ١-‫وا‬ ‫ا‬ ‫ت‬ ‫ﻡ‬ ‫ا‬: ‫أو‬-‫ن‬ ‫ا‬ ‫ر‬ ‫ا‬ ‫ا‬ ‫ﺏ‬:‫ح‬ ‫ﺝ‬‫ه‬‫ﺏ‬‫اﺝ‬ ‫ا‬ ‫ام‬ ‫ة‬ ‫ت‬ ‫ﺝ‬ ‫و‬. ‫ﺙ‬-‫وا‬ ‫زی‬ ‫ا‬ ‫ا‬ ‫ﺏ‬‫ا‬ ‫ا‬: -‫ﺏ‬ ‫ء‬ ‫ﺹ‬ ‫ا‬ ‫ح‬ ‫ا‬ ‫و‬ ‫و‬ ‫أ‬ ‫ه‬ ‫ا‬٧٠-٩٠%‫و‬‫ﺏ‬٦٠%‫ت‬ ‫ﺏ‬ ‫ا‬ ‫ﺏ‬ ‫إﺹ‬ ‫و‬ ‫ت‬ ‫أو‬ ‫ة‬ ‫ﺵ‬‫ﺏ‬ ‫ﺕ‬ ‫و‬٨٠.% ‫ة‬ ‫اﺉ‬ ‫ا‬ ‫ت‬ ‫و‬ ‫ا‬ ‫ا‬ ‫ﺕ‬ ‫ﺕ‬ ‫أآ‬ ‫ه‬ ‫ا‬ ‫ح‬ ‫ﺕ‬‫ح‬ ‫ا‬ ‫ت‬ ‫و‬. ‫ﺹ‬ ‫وﺕ‬ ‫ا‬ ‫ﺏ‬ ‫ور‬ ‫ﺕ‬ ‫ا‬ ‫ا‬ ‫ا‬ ‫ت‬ ‫و‬ ‫ﺹ‬ ‫ﺏ‬ ‫ا‬ ‫ا‬ ‫ﺹ‬ ‫ا‬ ‫ا‬ ‫م‬ ‫وﺕ‬ ‫م‬ ‫ﺏ‬ ‫ﺕ‬ ‫ا‬ ‫ا‬ ‫ت‬ ‫و‬ ‫و‬ ‫ت‬ ‫و‬ ‫ور‬ ‫ﺕ‬ ‫آ‬ ‫ا‬ ‫ث‬ ‫ا‬ ‫ت‬ ‫ا‬ ‫ف‬ ‫ﺕ‬ ‫آ‬ ‫ﺕ‬ ‫ام‬ ‫ﺏ‬. ‫ا‬‫و‬ ‫ﺏ‬‫ا‬ ‫ﺏ‬ ‫أ‬ ‫ل‬ ‫دة‬ ‫ا‬ ‫م‬ ‫ﺝ‬ ‫ا‬ ‫ﺕ‬. ‫ا‬ ‫ص‬ ‫ﺵ‬ ‫ا‬ ‫ﺏ‬ ‫ن‬ ‫آ‬ ‫واذا‬ ‫ض‬ ‫ﺏ‬ ‫ﺏ‬ ‫ﺹ‬ ‫ا‬ ‫ا‬ ‫ا‬ ‫ح‬‫رﺏ‬ ‫ا‬ ‫ا‬ ‫اض‬ ‫ﺏ‬ ‫ا‬ ‫أﺹ‬ ‫ﺏ‬ ‫ح‬ ‫ا‬ ‫أن‬ ‫ح‬ ‫ا‬ ‫ول‬ ‫ﺕ‬ ‫ﺏ‬ ‫ة‬ ‫ة‬ ‫وس‬ ‫ﺏ‬ ‫ﺏ‬ ‫ﺹ‬ ‫ا‬ ‫ﺕ‬‫أ‬ ‫ﺏ‬ ‫ﺏ‬ ‫دة‬ ‫ا‬ ‫م‬ ‫ﺝ‬ ‫ا‬ ‫ﺕ‬ ‫أ‬ ‫ا‬ ‫ا‬ ‫اض‬ ‫أ‬ ‫ﺕ‬ ‫اض‬ ‫أ‬ ‫وﺕ‬ ‫ا‬ ‫ا‬ ‫وس‬ ‫وب‬ ‫ﺏ‬ ‫ا‬ ‫أﺹ‬ ‫ورﺏ‬ ‫أ‬. ‫ﺏ‬ ‫ر‬ ‫وا‬ ‫ا‬ ‫ارة‬ ‫رﺝ‬ ‫ﺏ‬ ‫ع‬ ‫وارﺕ‬ ‫ا‬ ‫ن‬ ‫ﺏ‬ ‫ار‬ ‫إ‬ ‫وث‬ ‫ح‬ ‫ا‬ ‫اض‬ ‫ا‬ ‫ﺏ‬ ‫ﺝ‬ ‫ﺕ‬ ‫ا‬ ‫ج‬ ‫ﺕ‬ ‫و‬ ‫ون‬ ‫ﺏ‬ ‫أو‬ ‫م‬ ‫ل‬ ‫ﺕ‬ ‫اض‬ ‫ا‬ ‫ه‬ ‫وآ‬ ‫ا‬ ‫ان‬ ‫و‬ ‫ء‬ ‫و‬ ‫ل‬ ‫وإ‬ ‫اع‬ ‫ﺹ‬ ‫وث‬ ‫و‬ ‫د‬ ‫ﺝ‬ ‫وا‬ ‫اض‬ ‫ا‬ ‫ه‬ ‫ﺏ‬ ‫ارة‬ ‫ا‬ ‫ت‬ ‫ﺏ‬ ‫ام‬ ‫ا‬. ‫و‬ ‫ﺏ‬ ‫ﺹ‬ ‫ا‬ ‫ا‬ ‫ا‬ ‫ا‬ ‫ح‬ ‫رة‬ ‫ﺕ‬‫ا‬ ‫ودرﺝ‬ ‫ا‬‫ت‬ ‫وا‬ ‫ح‬ ‫ا‬ ‫ات‬ ‫ﺏ‬ ‫ﺏ‬ ‫ض‬ ‫ا‬ ‫ر‬ ‫ا‬ ‫ء‬ ‫أﺙ‬ ‫ة‬ ‫ﺉ‬ ‫ا‬. ‫و‬‫ت‬ ‫ﺏ‬ ‫ﺹ‬ ‫ا‬ ‫ن‬ ‫ﺕ‬‫ا‬ ‫و‬ ‫ﺏ‬ ‫أآ‬‫ا‬‫ت‬‫أ‬ ‫ﺕ‬ ‫ا‬‫ﺵ‬‫آ‬ ‫ا‬ ‫ا‬ ‫ص‬ ‫ا‬ ‫و‬ ‫وى‬ ‫ا‬ ‫ر‬ ‫ا‬ ‫ﺏ‬ ‫دة‬ ‫ا‬ ‫م‬ ‫ﺝ‬ ‫ا‬ ‫آ‬ ‫ص‬ ‫ﺕ‬ ‫أ‬. ‫أآ‬ ‫ص‬ ‫ﺵ‬ ‫ا‬ ‫ﺝ‬ ‫ﺕ‬٦‫ﺏ‬ ‫أﺵ‬‫ا‬‫أآ‬ ‫ص‬ ‫ﺵ‬ ‫وا‬ ‫اض‬ ‫ﺏ‬ ‫ن‬ ‫ﺏ‬ ‫وا‬ ‫ا‬ ‫وا‬ ‫ل‬٦٥ ‫ﺹ‬ ‫وﺕ‬ ‫ا‬ ‫ا‬ ‫و‬ ‫ا‬ ‫ا‬ ‫ا‬ ‫و‬ ‫ا‬ ‫ﺏ‬ ‫ا‬ ‫وﺝ‬ ‫ن‬ ‫ا‬ ‫ص‬ ‫ﺵ‬ ‫وا‬ ‫ا‬ ‫ت‬ ‫ا‬ ‫ﺏ‬ ‫ا‬ ‫ا‬‫ﺙ‬ ‫وا‬ ‫ا‬ ‫ﺹ‬ ‫ا‬ ‫ا‬ ‫اآ‬ ‫ن‬ ‫ا‬ ‫وه‬ ‫و‬ ‫ا‬ ‫درﺝ‬ ‫ﺕ‬ ‫ارد‬ ‫أ‬ ‫ﺉ‬ ‫و‬ ‫دون‬ ‫ﺙ‬ ‫ا‬ ‫وا‬ ‫ا‬ ‫ا‬ ‫ﺙ‬ ‫ت‬ ‫ﺏ‬ ‫ﺏ‬ ‫ا‬‫ﺏ‬‫و‬ ‫أﺵ‬ ‫ﺏ‬ ‫ل‬ ‫ا‬ ‫ﺙ‬.
  16. 16. ‫ا‬ ‫ا‬ ‫ح‬ ‫ع‬ ‫ا‬ ‫ص‬ ‫ﺵ‬ ‫ا‬ ‫آ‬‫اض‬ ‫أ‬ ‫ت‬ ‫وآ‬ ‫ﺏ‬ ‫ا‬ ‫ا‬ ‫ﺕ‬ ‫ة‬ ‫ﺵ‬ ‫ﺝ‬ ‫ر‬ ‫ﺙ‬ ‫ض‬ ‫ﺕ‬ ‫وآ‬ ‫ا‬ ‫ط‬ ‫ر‬ ‫ﺏ‬ ‫ن‬ ‫ﺝ‬ ‫ز‬Guillain-Barre syndrome‫ل‬٦‫أ‬ ‫ل‬ ‫وا‬ ‫ﺏ‬ ‫ا‬ ‫ا‬ ‫ﺕ‬ ‫ول‬ ‫ﺕ‬ ‫ﺏ‬ ‫أ‬٦‫أﺵ‬ ‫و‬ ‫ا‬ ‫ارة‬ ‫درﺝ‬ ‫ع‬ ‫إرﺕ‬ ‫وآ‬‫ا‬ ‫اض‬ ‫ا‬ ‫ﺝ‬ ‫زوال‬ ‫ر‬ ‫ا‬. ‫ری‬ ‫ﺏ‬ ‫ن‬ ‫زﻡ‬ ‫ﻡ‬‫ا‬ ‫اب‬ ‫ا‬ ‫د‬ ‫ا‬ ‫ب‬ ‫ا‬ ‫ب‬ ‫ا‬ ‫أو‬Acute inflammatory demylinating polyneuropathy‫ﺙ‬ ‫ا‬ ‫ور‬ ‫ا‬ ‫د‬ ‫ض‬ ‫ه‬‫ب‬ ‫ا‬‫داد‬ ‫و‬ ‫ر‬ ‫ا‬ ‫آ‬ ‫و‬ ‫ا‬ ‫ل‬ ‫ا‬ ‫ى‬ ‫وﺙ‬‫ض‬ ‫ا‬ ‫دي‬ ‫ب‬ ‫د‬ ‫ا‬ ‫ب‬ ‫ا‬ ‫و‬ ‫ا‬ ‫اء‬ ‫أﺝ‬ ‫ﺙ‬ ‫ﺏ‬ ‫ا‬ ‫اء‬ ‫ﺝ‬ ‫ا‬ ‫دى‬ ‫و‬ ‫ى‬ ‫أ‬ ‫دة‬ ‫و‬ ‫ب‬ ‫ﺏ‬ ‫ا‬ ‫ء‬ ‫ا‬ ‫وه‬ ‫ا‬ ‫زا‬‫ا‬ ‫ور‬ ‫ا‬‫ﺏ‬ ‫و‬ ‫ا‬ ‫ب‬ ‫ﺙ‬ ‫ل‬ ‫ﺕ‬ ‫ا‬ ‫ا‬ ‫ا‬ ‫ت‬ ‫أن‬ ‫ن‬ ‫ا‬‫ا‬ ‫ا‬ ‫ا‬ ‫وس‬ ‫ﺏ‬ ‫ﺏ‬ ‫ﺹ‬ ‫ا‬ ‫إن‬ ‫ى‬ ‫أ‬ ‫د‬ ‫ا‬ ‫و‬ ‫ر‬ ‫ﺏ‬ ‫ن‬ ‫ﺝ‬ ‫ز‬ ‫ت‬ ‫ا‬ ‫اﺕ‬ ‫ﺏ‬)‫إ‬ ‫ﺕ‬١١٠٠٠٠(‫ى‬ ‫ا‬ ‫أ‬ ‫ى‬ ‫ر‬ ‫ﺏ‬ ‫ن‬ ‫ﺝ‬ ‫ز‬ ‫ﺏ‬ ‫ﺏ‬ ‫ﺹ‬ ‫ا‬ ‫وﺕ‬ ‫ح‬ ‫ا‬ ‫ﺏ‬ ‫ا‬. ٢-‫واﺉ‬ ‫ا‬ ‫ت‬ ‫ﻡ‬ ‫ا‬ ‫أدو‬ ‫ك‬ ‫ه‬‫وﺕ‬ ‫ﺏ‬ ‫ﺝ‬ ‫و‬ ‫ض‬ ‫ا‬‫ن‬ ‫د‬ ‫ا‬)‫د‬ ‫وا‬ ‫د‬ ‫ا‬(‫و‬‫ت‬ ‫از‬ ‫را‬)‫ا‬ ‫وا‬ ‫و‬ ‫ا‬(‫وﺕ‬‫و‬ ‫ا‬ ‫ا‬ ‫ت‬ ‫و‬ ‫ﺏ‬‫ح‬ ‫ت‬ ‫و‬ ‫دة‬ ‫ا‬ ‫دو‬ ‫ا‬ ‫ا‬ ‫م‬ ‫وﺕ‬ ‫ج‬ ‫وا‬ ‫ا‬‫ت‬ ‫و‬ ‫دة‬ ‫ا‬ ‫دو‬ ‫ا‬ ‫إزاء‬ ‫ة‬ ‫اﺉ‬ ‫ا‬ ‫ا‬ ‫ا‬ ‫ت‬ ‫و‬ ‫ﺹ‬ ‫ﺏ‬ ‫ا‬ ‫ت‬ ‫و‬ ‫دة‬ ‫أدو‬ ‫ودون‬ ‫ر‬ ‫أ‬ ‫دون‬ ‫ض‬ ‫ا‬ ‫ﺕ‬ ‫ﺵ‬ ‫ﺏ‬ ‫ُﺏ‬‫أ‬ ‫ا‬ ‫ز‬ ‫ا‬ ‫ا‬ ‫إ‬‫درﺝ‬ ‫ع‬ ‫ارﺕ‬ ‫و‬ ‫ل‬ ‫را‬ ‫ا‬ ‫ة‬ ‫ﺏ‬ ‫ا‬ ‫ارة‬‫دي‬ ‫ل‬ ‫ا‬ ‫ء‬ ‫ا‬ ‫و‬ ‫و‬ ‫ﺏ‬ ‫وا‬‫راي‬ ‫ز‬ Reye's syndrome‫ﺏ‬ ‫ا‬ ‫ا‬ ‫ا‬ ‫ا‬ ‫ر‬ ‫آ‬ ‫وا‬ ‫ف‬ ‫ا‬ ‫و‬ ‫اﺉ‬ ‫ا‬ ‫ب‬ ‫ﺵ‬ ‫ر‬ ‫آ‬ ‫ا‬. ‫ری‬ ‫ﺏ‬ ‫ن‬ ‫زﻡ‬ ‫ﻡ‬‫ا‬ ‫اب‬ ‫ا‬ ‫د‬ ‫ا‬ ‫ب‬ ‫ا‬ ‫ب‬ ‫ا‬ ‫أو‬Acute inflammatory demylinating polyneuropathy‫ﺙ‬ ‫ا‬ ‫ور‬ ‫ا‬ ‫د‬ ‫ض‬ ‫ه‬‫ب‬ ‫ا‬‫ى‬ ‫وﺙ‬ ‫داد‬ ‫و‬ ‫ر‬ ‫ا‬ ‫آ‬ ‫و‬ ‫ا‬ ‫وه‬ ‫ا‬ ‫زا‬ ‫ض‬ ‫ا‬ ‫دي‬ ‫ب‬ ‫د‬ ‫ا‬ ‫ب‬ ‫ا‬ ‫و‬ ‫ا‬ ‫اء‬ ‫أﺝ‬ ‫ﺙ‬ ‫ﺏ‬ ‫ا‬ ‫اء‬ ‫ﺝ‬ ‫ا‬ ‫دى‬ ‫و‬ ‫ل‬ ‫ا‬ ‫ى‬ ‫أ‬ ‫دة‬ ‫و‬ ‫ب‬ ‫ﺏ‬ ‫ا‬ ‫ء‬ ‫ا‬‫ا‬ ‫ور‬ ‫ا‬‫ا‬ ‫ا‬ ‫ا‬ ‫ت‬ ‫أن‬ ‫ن‬ ‫ا‬ ‫ﺏ‬ ‫و‬ ‫ا‬ ‫ب‬ ‫ﺙ‬ ‫ت‬ ‫ا‬ ‫اﺕ‬ ‫ﺏ‬ ‫ا‬ ‫ا‬ ‫ا‬ ‫وس‬ ‫ﺏ‬ ‫ﺏ‬ ‫ﺹ‬ ‫ا‬ ‫إن‬ ‫ى‬ ‫أ‬ ‫د‬ ‫ا‬ ‫و‬ ‫ر‬ ‫ﺏ‬ ‫ن‬ ‫ﺝ‬ ‫ز‬ ‫ل‬ ‫ﺕ‬)‫ﺕ‬ ‫إ‬١١٠٠٠٠(‫ح‬ ‫ا‬ ‫ﺏ‬ ‫ا‬ ‫ى‬ ‫ا‬ ‫أ‬ ‫ى‬ ‫ر‬ ‫ﺏ‬ ‫ن‬ ‫ﺝ‬ ‫ز‬ ‫ﺏ‬ ‫ﺏ‬ ‫ﺹ‬ ‫ا‬ ‫وﺕ‬. ٢-‫واﺉ‬ ‫ا‬ ‫ت‬ ‫ﻡ‬ ‫ا‬ ‫وﺕ‬ ‫ﺏ‬ ‫ﺝ‬ ‫و‬ ‫ض‬ ‫ا‬ ‫أدو‬ ‫ك‬ ‫ه‬‫ن‬ ‫د‬ ‫ا‬)‫د‬ ‫وا‬ ‫د‬ ‫ا‬(‫و‬‫ت‬ ‫از‬ ‫را‬)‫ا‬‫ا‬ ‫وا‬ ‫و‬(‫وﺕ‬‫و‬ ‫ا‬ ‫ا‬ ‫ت‬ ‫و‬ ‫ﺏ‬‫ح‬ ‫ت‬ ‫و‬ ‫دة‬ ‫ا‬ ‫دو‬ ‫ا‬ ‫ت‬ ‫و‬ ‫دة‬ ‫ا‬ ‫دو‬ ‫ا‬ ‫إزاء‬ ‫ة‬ ‫اﺉ‬ ‫ا‬ ‫ا‬ ‫ا‬ ‫ت‬ ‫و‬ ‫ﺹ‬ ‫ﺏ‬ ‫ا‬ ‫ا‬ ‫م‬ ‫وﺕ‬ ‫ج‬ ‫وا‬ ‫ا‬ ‫ُﺏ‬‫أ‬ ‫ا‬ ‫ز‬ ‫ا‬ ‫ا‬ ‫إ‬‫ت‬ ‫و‬ ‫دة‬ ‫أدو‬ ‫ودون‬ ‫ر‬ ‫أ‬ ‫دون‬ ‫ض‬ ‫ا‬ ‫ﺕ‬ ‫ﺵ‬ ‫ﺏ‬‫درﺝ‬ ‫ع‬ ‫ارﺕ‬ ‫و‬ ‫دي‬ ‫ل‬ ‫ا‬ ‫ء‬ ‫ا‬ ‫و‬ ‫و‬ ‫ﺏ‬ ‫وا‬ ‫ل‬ ‫را‬ ‫ا‬ ‫ة‬ ‫ﺏ‬ ‫ا‬ ‫ارة‬‫راي‬ ‫ز‬ Reye's syndrome‫و‬ ‫اﺉ‬ ‫ا‬ ‫ب‬ ‫ﺵ‬ ‫ر‬ ‫آ‬ ‫ا‬‫ﺏ‬ ‫ا‬ ‫ا‬ ‫ا‬ ‫ا‬ ‫ر‬ ‫آ‬ ‫وا‬ ‫ف‬ ‫ا‬. ‫ﻡ‬:‫راي‬ ‫ز‬Reye's syndrome‫أ‬ ‫ث‬ ‫د‬ ‫ض‬ ‫ه‬‫أو‬ ‫ري‬ ‫وا‬ ‫ا‬ ‫ﺏ‬ ‫ﺏ‬ ‫ﺹ‬ ‫ا‬ ‫ﺏ‬ ‫ل‬ ‫ا‬ ‫ن‬ ‫ه‬ ‫ا‬ ‫ﺕ‬ ‫إ‬ ‫دي‬ ‫و‬ ‫ى‬ ‫أ‬ ‫و‬ ‫وى‬ ‫أي‬‫ﺏ‬‫و‬ ‫ض‬ ‫ا‬ ‫ا‬ ‫ه‬ ‫وأآ‬ ‫غ‬ ‫ا‬ ‫وورم‬‫ا‬ ‫ا‬ ‫اض‬ ‫ا‬ ‫ة‬ ‫ل‬ ‫راي‬١٩٦٣‫و‬‫أ‬‫ﺕ‬ ‫أن‬ ‫ا‬ ‫و‬ ‫و‬ ‫ض‬ ‫ء‬ ‫ا‬ ‫ة‬ ‫ل‬ ‫دة‬ ‫ث‬ ‫ﺕ‬‫ث‬‫ا‬ ‫ﺏ‬ ‫أ‬ ‫ر‬ ‫ار‬ ‫ﺏ‬‫أو‬‫آ‬ ‫ﺕ‬ ‫ا‬‫آ‬‫ل‬ ‫ﺏ‬ ‫ﺕ‬ ‫أ‬‫ا‬‫و‬ ‫ا‬ ‫ض‬ ‫ا‬ ‫ل‬ ‫ت‬ ‫ا‬ ‫أو‬. ٣-‫ارئ‬ ‫ا‬ ‫ت‬ ‫ﻡ‬ ‫ﻡ‬ ‫ا‬ ‫اض‬ ‫ا‬ ‫ر‬ ‫ل‬ ‫ا‬ ‫رة‬ ‫ﺏ‬ ‫در‬ ‫ﺏ‬ ‫ا‬ ‫ا‬ ‫اض‬ ‫ﺏ‬ ‫ﺏ‬ ‫ﺹ‬ ‫ا‬: ‫أو‬-‫ا‬:‫ﺕ‬ ‫ﺏ‬ ‫ﺹ‬‫و‬‫ور‬ ‫ﺏ‬ ‫ا‬ ‫ﺕ‬ ‫وإذا‬ ‫ﺏ‬ ‫أو‬ ‫ﺝ‬ ‫وآ‬ ‫و‬ ‫د‬ ‫ء‬ ‫و‬ ‫ا‬ ‫اب‬ ‫وإ‬ ‫أ‬٣ ‫أ‬ ‫أ‬ ‫ل‬ ‫و‬ ‫ﺏ‬ ‫اض‬ ‫ا‬ ‫ودة‬ ‫أو‬ ‫م‬ ‫أ‬. ‫ﺙ‬-‫ل‬ ‫ا‬:‫ا‬‫و‬ ‫ا‬‫ﺏ‬ ‫ﺹ‬‫رق‬ ‫ا‬ ‫ا‬ ‫ن‬ ‫و‬ ‫ا‬‫أ‬‫أو‬ ‫ا‬ ‫ﺕ‬ ‫ة‬ ‫وﺵ‬ ‫د‬ ‫ء‬ ‫و‬ ‫دى‬ ‫ا‬ ‫و‬‫ن‬ ‫أ‬ ‫أ‬ ‫ل‬ ‫و‬ ‫ﺏ‬ ‫ى‬ ‫أ‬ ‫ة‬ ‫دة‬ ‫ا‬ ‫ﺙ‬ ‫ا‬ ‫ا‬ ‫ﺕ‬ ‫ا‬ ‫اض‬ ‫ا‬ ‫ﺕ‬ ‫أو‬ ‫ﺏ‬ ‫أو‬ ‫ﺝ‬ ‫وآ‬ ‫آ‬ ‫أو‬ ‫ل‬. ٤-‫آ‬ ‫ا‬ ‫ت‬ ‫ﻡ‬ ‫ا‬ -‫ﺏ‬ ‫وا‬ ‫ا‬ ‫ﺕ‬‫ا‬ ‫د‬ ‫ا‬ ‫ء‬ ‫وا‬ ‫وا‬ ‫ل‬ ‫ا‬ ‫ور‬‫ﺏ‬‫ت‬ ‫ا‬. -‫ا‬‫ﺏ‬‫ء‬‫و‬‫وا‬ ‫ا‬ ‫ا‬ ‫ع‬ ‫وا‬ ‫ن‬ ‫ﺏ‬ ‫ا‬‫و‬‫ة‬ ‫ل‬ ‫اا‬ ‫وﺕ‬ ‫ا‬ ‫اب‬ ‫ا‬ ‫م‬ ‫ا‬ ‫ﺏ‬ ‫أآ‬ ‫أو‬ ‫ء‬ ‫وا‬ ‫ل‬ ‫وا‬ ‫وى‬ ‫ا‬. -‫ا‬‫ا‬ ‫وأوا‬ ‫ا‬ ‫ات‬ ‫آ‬ ‫ا‬ ‫اض‬ ‫ك‬ ‫ا‬ ‫ل‬‫آ‬‫وا‬ ‫ا‬ ‫ات‬ ‫وا‬.
  17. 17. -‫ﺕ‬ ‫ة‬ ‫ل‬ ‫ﺏ‬ ‫ﺏ‬ ‫ا‬ ‫ص‬ ‫ﺵ‬ ‫ا‬ ‫ء‬ ‫ﺏ‬٢٤‫ر‬ ‫وا‬ ‫ب‬ ‫ه‬ ‫ا‬ ‫م‬ ‫و‬ ‫ا‬ ‫زوال‬ ‫ﺏ‬. -‫ا‬ ‫وا‬ ‫ق‬ ‫ا‬ ‫وﺕ‬ ‫د‬ ‫ا‬ ‫آ‬ ‫اا‬ ‫ﺕ‬‫ا‬ ‫وا‬ ‫ت‬ ‫آ‬ ‫م‬ ‫ا‬. -‫ة‬ ‫رة‬ ‫ﺏ‬ ‫ا‬ ‫ﺏ‬ ‫م‬ ‫وا‬ ‫و‬ ‫ﺹ‬ ‫أ‬ ‫ول‬ ‫وﺕ‬ ‫آ‬ ‫ة‬ ‫م‬ ‫ا‬. ‫ا‬ ‫ا‬‫ة‬ ‫ا‬ ‫وا‬. -‫ﺵ‬ ‫ا‬ ‫ل‬ ‫ﺕ‬ ‫ا‬ ‫ﺕ‬‫ﺏ‬‫و‬ ‫ا‬ ‫ا‬‫ا‬‫ا‬ ‫ﺕ‬ ‫ك‬ ‫ﺕ‬. -‫ا‬ ‫ا‬ ‫ز‬ ‫ا‬ ‫اﺉ‬ ‫ا‬ ‫ول‬ ‫وﺕ‬ ‫ا‬ ‫ا‬ ‫ا‬ ‫ط‬ ‫وا‬ ‫اﺉ‬ ‫ا‬ ‫ازن‬ ‫ا‬ ‫ظ‬ ‫ا‬. -‫ا‬ ‫ا‬. -‫ﺏ‬ ‫ا‬ ‫ا‬ ‫ت‬ ‫ا‬ ‫ه‬ ‫م‬ ‫ا‬ ‫وأدوات‬ ‫ت‬ ‫آ‬ ‫ب‬ ‫ا‬ ‫ا‬ ‫أدوات‬. ‫ﺉ‬ ‫ﺏ‬ ‫ا‬ ‫وﻡ‬ ‫ﻡ‬ ‫ودوره‬ ‫ة‬ ‫وا‬ ‫ا‬‫ت‬ -‫ﺕ‬ ‫ا‬ ‫ل‬"‫آ‬ ‫ﺕ‬ ‫آ‬ ‫و‬ ‫رﺝ‬ ‫ك‬ ‫ﺕ‬ ‫ﺏ‬ ‫س‬ ‫ا‬ ‫وأذن‬"‫أ‬ ‫ل‬ ‫و‬"‫ة‬ ‫وا‬ ‫ا‬ ‫ا‬ ‫وأﺕ‬" ‫ا‬ ‫ا‬ ‫ق‬ ‫ﺹ‬. -‫ت‬ ‫ا‬ ‫ا‬ ‫ء‬ ‫أ‬ ‫آ‬ ‫د‬ ‫ا‬ ‫ا‬ ‫ا‬ ‫م‬ ‫وآ‬ ‫ا‬ ‫ف‬‫و‬ ‫ق‬ ‫ا‬‫وا‬ ‫ا‬ ‫ا‬‫و‬ ‫خ‬ ‫ﺕ‬‫ﺙ‬‫آ‬‫ﺉ‬ ‫ووﺏ‬ ‫ﺝ‬ ‫ﺏ‬ ‫ت‬ ‫ا‬ ‫د‬ ‫وﺝ‬‫و‬. -‫ا‬ ‫ا‬ ‫ا‬ ‫ا‬ ‫ه‬ ‫ر‬٦‫ات‬. -‫آ‬‫دم‬‫ا‬ ‫ا‬ ‫ا‬‫ا‬ ‫ا‬‫وا‬ ‫ا‬ ‫ﺕ‬ ‫آ‬ ‫أ‬ ‫و‬ ‫أن‬ ‫ن‬ ‫ﺕ‬‫ﺏ‬‫ة‬‫ا‬‫ا‬‫ا‬‫ة‬Cosmopolitan antigenic pool‫ون‬ ‫وا‬ ‫ج‬ ‫ا‬ ‫دل‬ ‫ﺏ‬ ‫ﺕ‬‫ا‬‫ﺕ‬‫ا‬ ‫ا‬‫وا‬ ‫ﺉ‬ ‫ﺏ‬ ‫ا‬. -‫أ‬ ‫أآ‬ ‫ي‬ ‫أ‬ ‫ة‬ ‫ره‬ ‫د‬ ‫ا‬ ‫آ‬ ‫ون‬ ‫وا‬ ‫ج‬ ‫ا‬ ‫د‬‫ا‬ ‫ا‬ ‫ة‬ ‫ﺝ‬ ‫ت‬ ‫ﺙ‬ ‫ﺕ‬ ‫د‬ ‫ﺕ‬ ‫و‬ ‫أ‬ ‫ﺏ‬ ‫ﺕ‬ ‫ا‬ ‫وﺏ‬ ‫ا‬ ‫ا‬ ‫ا‬ ‫ا‬ ‫ﺏ‬ ‫ة‬ ‫ا‬ ‫ا‬ ‫ا‬ ‫ه‬ ‫زع‬ ‫وﺕ‬. ‫أي‬‫اآ‬ ‫وﺕ‬ ‫آ‬ ‫أ‬ ‫ﺕ‬ ‫و‬ ‫أ‬ ‫ﺏ‬ ‫ن‬ ‫ة‬ ‫وا‬ ‫ا‬ ‫أن‬. Avian fluSeasonal fluSwine FluColdDiseases H5N1 + H7N1H1N1 + H3N2 H1N1 + H1N2 +H3N1 Rhinovirus Coronavirus& Hemophilus influenza Cause All systems.Respiratory Respiratory& digestive UpperrespiratorySystem affected No.Rapid.Rapid.Rapid.Contagiousness Always presentAlways present Always present Rare.Fever DryDryDryProductiveCoughing CommonModerateCommonAlwaysAches Not common Runny nose is present. Not commonCommonStuffy nose Severe. Mild to moderate. Severe.Uncommon.Chills Moderate tosevere.Moderate. Moderate to severe. Fairly mild.Tiredness Not common.Common.Not common.Common.Sneezing NoNoYesNoDrowsiness Loss of appetite indigestion,tympani, constipationdark urine andsevere conjunctivitis. Flushed face، loss of appetite، dizziness and/or vomiting or nausea. Fever, aches andpains. Diarrhea is common. Cold symptoms tend to develop over a few days. SuddenSymptoms CommonFairly common.Common Fairly uncommon. Headache CommonCommonNot commonCommonSore Throat Severe.Moderate.Severe.Mild tomoderate.Chest pain

×